263 related articles for article (PubMed ID: 26453883)
21. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase).
Gandhi NS; Freeman C; Parish CR; Mancera RL
Glycobiology; 2012 Jan; 22(1):35-55. PubMed ID: 21746763
[TBL] [Abstract][Full Text] [Related]
22. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.
Ilan N; Elkin M; Vlodavsky I
Int J Biochem Cell Biol; 2006; 38(12):2018-39. PubMed ID: 16901744
[TBL] [Abstract][Full Text] [Related]
23. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
24. Non-anti-coagulant heparins: a promising approach for prevention of tumor metastasis (review).
Kragh M; Loechel F
Int J Oncol; 2005 Oct; 27(4):1159-67. PubMed ID: 16142335
[TBL] [Abstract][Full Text] [Related]
25. High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase.
Bisio A; Mantegazza A; Urso E; Naggi A; Torri G; Viskov C; Casu B
Semin Thromb Hemost; 2007 Jul; 33(5):488-95. PubMed ID: 17629845
[TBL] [Abstract][Full Text] [Related]
26. Preparation of low molecular weight heparin using an ultrasound-assisted Fenton-system.
Zhi Z; Li J; Chen J; Li S; Cheng H; Liu D; Ye X; Linhardt RJ; Chen S
Ultrason Sonochem; 2019 Apr; 52():184-192. PubMed ID: 30559077
[TBL] [Abstract][Full Text] [Related]
27. Design of an Ultralow Molecular Weight Heparin That Resists Heparanase Biodegradation.
Ham H; Xu Y; Haller CA; Dai E; Stancanelli E; Liu J; Chaikof EL
J Med Chem; 2023 Feb; 66(3):2194-2203. PubMed ID: 36706244
[TBL] [Abstract][Full Text] [Related]
28. Polymeric fluorescent heparin as one-step FRET substrate of human heparanase.
Sistla JC; Morla S; Alabbas AB; Kalathur RC; Sharon C; Patel BB; Desai UR
Carbohydr Polym; 2019 Feb; 205():385-391. PubMed ID: 30446119
[TBL] [Abstract][Full Text] [Related]
29. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
30. Implications of Heparanase on Heparin Synthesis and Metabolism in Mast Cells.
Maccarana M; Jia J; Li H; Zhang X; Vlodavsky I; Li JP
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563215
[TBL] [Abstract][Full Text] [Related]
31. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
32. Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.
Walenga JM; Lyman GH
Crit Rev Oncol Hematol; 2013 Oct; 88(1):1-18. PubMed ID: 23849978
[TBL] [Abstract][Full Text] [Related]
33. Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo.
Poli M; Asperti M; Ruzzenenti P; Mandelli L; Campostrini N; Martini G; Di Somma M; Maccarinelli F; Girelli D; Naggi A; Arosio P
Biochem Pharmacol; 2014 Dec; 92(3):467-75. PubMed ID: 25241290
[TBL] [Abstract][Full Text] [Related]
34. Family of Bioactive Heparin-Coated Iron Oxide Nanoparticles with Positive Contrast in Magnetic Resonance Imaging for Specific Biomedical Applications.
Groult H; Poupard N; Herranz F; Conforto E; Bridiau N; Sannier F; Bordenave S; Piot JM; Ruiz-Cabello J; Fruitier-Arnaudin I; Maugard T
Biomacromolecules; 2017 Oct; 18(10):3156-3167. PubMed ID: 28850787
[TBL] [Abstract][Full Text] [Related]
35. Investigating Glycol-Split-Heparin-Derived Inhibitors of Heparanase: A Study of Synthetic Trisaccharides.
Ni M; Elli S; Naggi A; Guerrini M; Torri G; Petitou M
Molecules; 2016 Nov; 21(11):. PubMed ID: 27886097
[TBL] [Abstract][Full Text] [Related]
36. The impact of heparanese and heparin on cancer metastasis and angiogenesis.
Vlodavsky I; Abboud-Jarrous G; Elkin M; Naggi A; Casu B; Sasisekharan R; Ilan N
Pathophysiol Haemost Thromb; 2006; 35(1-2):116-27. PubMed ID: 16855356
[TBL] [Abstract][Full Text] [Related]
37. Catalytic Effects of Different Heparin Analogs on the Hydrolysis of Auramine O.
He Y; Li J; Chen Y
J Biomater Sci Polym Ed; 2011; 22(1-3):253-61. PubMed ID: 20557699
[TBL] [Abstract][Full Text] [Related]
38. Development of both colorimetric and fluorescence heparinase activity assays using fondaparinux as substrate.
Schiemann S; Lühn S; Alban S
Anal Biochem; 2012 Aug; 427(1):82-90. PubMed ID: 22579846
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky I; Mohsen M; Lider O; Svahn CM; Ekre HP; Vigoda M; Ishai-Michaeli R; Peretz T
Invasion Metastasis; 1994-1995; 14(1-6):290-302. PubMed ID: 7657522
[TBL] [Abstract][Full Text] [Related]
40. Antimetastatic activities of heparins and modified heparins. Experimental evidence.
Borsig L
Thromb Res; 2010 Apr; 125 Suppl 2():S66-71. PubMed ID: 20434009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
